Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
guizhilongmu prescription + shudipingchan prescription is a combination of two Traditional Chinese Medicine (TCM) formulas used for the treatment of Parkinson's disease. The first component, Gui Zhi Jia Long Gu Mu Li Tang (guizhilongmu prescription), is a classic formula originating from the *Shanghan Lun* (Treatise on Febrile Diseases) that is traditionally used to harmonize the 'Ying' and 'Wei' levels, stabilize the spirit, and treat symptoms such as palpitations, insomnia, and irritability. The second component, Shudi Pingchan Tang (shudipingchan prescription), is a modern TCM formula specifically designed to nourish the liver and kidney 'Yin' and extinguish internal 'wind' to alleviate tremors and rigidity. Clinical research, particularly in China, has investigated this combination for its potential to improve both motor symptoms (tremor, bradykinesia) and non-motor symptoms (sleep disturbances, anxiety) in Parkinson's patients, likely through neuroprotective mechanisms and modulation of the dopaminergic system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guizhilongmu prescription + shudipingchan prescription.